Approval · Notice of Compliance 20122 · 2017
RENFLEXIS: Notice of Compliance 20122
Issued December 1, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20122
- Date
- December 1, 2017
- Company
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RENFLEXIS | 02470373 | Marketed |
Medicinal ingredients
- INFLIXIMAB 100 MG per VIAL